CLB Stock Price | Core Laboratories NV P/E, Revenue, EPS, & Forecasts

Core Laboratories NV • CLB

CLB current price

$16.81-9.43%

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs
News

-9.77%

-18.60%

-5.77%

-14.89%

-9.43%

MAX

-84.45%

Calendar

event

Ex dividend date

04 Nov 2024

event_available

Last Dividend Payment

25 Nov 2024

About Core Laboratories NV

Ticker

CLB

Trading on

NYSE

ISIN

US21867A1051

Industry

Oil & Gas Equipment & Services

Sector

Energy

CEO

Lawrence V. Bruno

Headquarters

6316 Windfern Road, Houston, TX, United States, 77040

Employees

3,500

Website

corelab.com

Core Laboratories Inc. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies, as well as services that support carbon capture, utilization and storage, geothermal projects, and the evaluation and appraisal of mining activities. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, production, and well abandonment. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. The company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. Core Laboratories Inc. was founded in 1936 and is based in Houston, Texas.

Metrics

BasicAdvanced

Market cap

$794M

P/E ratio

31.33

EPS

$0.54

Dividend Yield

0.24%

Beta

2.36

Forward P/E ratio

17.92

EBIDTA

$71.4M

Ex dividend date

2024-11-04

Price & volume

Market cap

$794M

Average daily volume

0.3M

90-day return

-5.77%

30-day return

-18.60%

7-day return

-9.77%

Dividends

Dividend per share

$0.04

Dividend yield

0.24%

Forward dividend per share

$0.04

Forward dividend yield

0.24%

Payout ratio

4.71%

Valuation

P/E ratio

31.33

Forward P/E

17.92

PEG ratio

1.51

Trailing P/E

31.33

Price to sales

1.52

Price to book

3.15

Earnings

EPS

$0.54

EPS estimate (current quarter)

$0.23

EPS estimate (next quarter)

$0.25

EBITDA

$71.4M

Revenues (TTM)

$523M

Revenues per share (TTM)

$11.16

Technicals

Beta

2.36

52-week High

$25.11

52-week Low

$13.80

50-day moving average

$19.51

200-day moving average

$18.90

Short ratio

23.15

Short %

26.80%

Management effectiveness

ROE (TTM)

11.16%

ROA (TTM)

5.89%

Profit margin

5.01%

Gross profit margin

$96.1M

Operating margin

12.35%

Growth

Quarterly earnings growth (YoY)

31.60%

Quarterly revenue growth (YoY)

7.20%

Share stats

Outstanding Shares

47M

Float

46.5M

Insiders %

0.86%

Institutions %

112.62%

Analyst Insights & forecasts

17% Buy

50% Hold

33% Sell

Based on information from 6 analysts.

Average price target

$19.33

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

$0.19

Q4 • 23Beat

$0.19

$0.16

18.75%

Q1 • 24Beat

$0.22

$0.21

4.76%

Q2 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$131M

$9M

6.92%

Q2 • 24

$134M

$11.7M

8.74%

Q3 • 24

2.93%

30.04%

26.34%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$598M

$352M

58.90%

Q2 • 24

$600M

$344M

57.30%

Q3 • 24

0.45%

2.29%

2.72%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$17.1M

$-0.7M

$-13.6M

$14.2M

Q2 • 24

$13.6M

$-0.5M

$-9.2M

$10.4M

Q3 • 24

20.49%

28.53%

32.56%

27.03%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Core Laboratories NV share?

Core Laboratories NV shares are currently traded for $16.81 per share.

How many shares does Core Laboratories NV have?

Core Laboratories NV currently has 47M shares.

Does Core Laboratories NV pay dividends?

Yes, Core Laboratories NV does pay dividends.

What is Core Laboratories NV 52 week high?

Core Laboratories NV 52 week high is $25.11.

What is Core Laboratories NV 52 week low?

Core Laboratories NV 52 week low is $13.80.

What is the 200-day moving average of Core Laboratories NV?

Core Laboratories NV 200-day moving average is $18.90.

Who is Core Laboratories NV CEO?

The CEO of Core Laboratories NV is Lawrence V. Bruno.

How many employees Core Laboratories NV has?

Core Laboratories NV has 3,500 employees.

What is the market cap of Core Laboratories NV?

The market cap of Core Laboratories NV is $794M.

What is the P/E of Core Laboratories NV?

The current P/E of Core Laboratories NV is 31.33.

What is the EPS of Core Laboratories NV?

The EPS of Core Laboratories NV is $0.54.

What is the PEG Ratio of Core Laboratories NV?

The PEG Ration of Core Laboratories NV is 1.51.

What do analysts say about Core Laboratories NV?

According to the analysts Core Laboratories NV is considered a hold.

Core Laboratories NV news

thumbs_up_down

•Neutral

Clinical Chemistry and Immunoassay Industry Forecast Report to 2028: Integrated and Scalable Core Lab Solutions Driving Transformational Growth

Dublin, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The "Clinical Chemistry and Immunoassay Industry, Global, 2023-2028" report has been added to ResearchAndMarkets.com's offering. This analysis examines the global clinical chemistry and immunoassay sector, accounting for the highest share in the in vitro diagnostics (IVD) market. This type of lab-based testing analyzes body fluids (usually blood, urine, or saliva) using integrated/standalone analyzers and a wide range of assays/panels, among other solutions and services to support the diagnosis and treatment of human health. While clinical chemistry instruments and tests target different chemicals in body fluids to evaluate health and the clinical management of patients, immunoassay instruments and tests measure the presence or concentration of analytes in biological liquid by using the binding of antibodies to antigens to identify and measure certain substances. This competitive analysis examines IVD companies that provide a broad menu of clinical chemistry and immunoassay systems, including instruments and consumables.

GlobeNewsWire•17 Dec 2024, 19:20

thumbs_up_down

•Neutral

Is Now the Right Time to Buy Core Laboratories After Its 12% YTD Rise?

CLB shows strong earnings growth, solid cash flow and innovative technologies, but faces risks from geopolitical tensions, weak U.S. onshore activity and oil price volatility.

Zacks Investment Research•13 Dec 2024, 12:51

thumb_up_alt

•Positive

Why Is Core Laboratories (CLB) Up 11.5% Since Last Earnings Report?

Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research•22 Nov 2024, 17:37